Lista de obras - Yvonne Freund-Levi - Dominio Público Uruguay

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

scientific article published on 18 December 2019

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia

artículo científico publicado en 2020

Agitation in dementia: relation to core cerebrospinal fluid biomarker levels

artículo científico publicado en 2014

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.

artículo científico publicado en 2018

Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study

artículo científico publicado en 2017

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

artículo científico publicado en 2017

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

scientific article published on 13 September 2019

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

artículo científico publicado en 2019

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

artículo científico publicado en 2022

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

artículo científico publicado en 2017

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

artículo científico publicado en 2018

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

artículo científico publicado en 2009

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

artículo científico publicado en 2020

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

artículo científico publicado en 2019

Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

artículo científico publicado en 2017

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

scientific article published on 01 June 2019

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

artículo científico publicado en 2012

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

artículo científico publicado en 2017

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.

artículo científico publicado en 2008

Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study

artículo científico publicado en 2015

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

artículo científico publicado en 2009

Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study

artículo científico publicado en 2014

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study

artículo científico publicado en 2013

Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study

artículo científico publicado en 2014

Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial

artículo científico publicado en 2013

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

artículo científico publicado en 2019

Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid

artículo científico

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

artículo científico publicado en 2017

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

scientific article published on 06 April 2019

Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients

artículo científico publicado en 2013

Neuropsychiatric symptoms in dementia-a role for neuroinflammation?

artículo científico publicado en 2014

Nutritional Considerations for Healthy Aging and Reduction in Age-Related Chronic Disease

artículo científico publicado en 2017

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

artículo científico publicado en 2008

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

artículo científico publicado en 2006

Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers

artículo científico publicado en 2013

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

artículo científico

Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited

artículo científico publicado en 2007

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

artículo científico

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

artículo científico publicado en 2017

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage

artículo científico publicado en 2015

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

artículo científico publicado en 2009

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

artículo científico publicado en 2015

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

artículo científico publicado en 2018

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

scientific article published on 08 May 2019

Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study

artículo científico publicado en 2009

Response to Bogaiksy's letter to the editor

artículo científico publicado en 2014

The frequency and influence of dementia risk factors in prodromal Alzheimer's disease

artículo científico publicado en 2017

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.

artículo científico publicado en 2014

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort

scientific article published on 01 January 2020

[Administration of symptom-relieving drugs in Alzheimer disease is beneficial]

scientific article published on 01 February 2006

Lista de obras de Yvonne Freund-Levi

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

Agitation and impulsivity in mid and late life as possible risk markers for incident dementia

Agitation in dementia: relation to core cerebrospinal fluid biomarker levels

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.

Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.

Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study

Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study

Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial

Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study

Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients

Neuropsychiatric symptoms in dementia-a role for neuroinflammation?

Nutritional Considerations for Healthy Aging and Reduction in Age-Related Chronic Disease

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

Omega-3-fatty acids protect against dementia. Also early symptoms of mild Alzheimer disease seem to be inhibited

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study

Response to Bogaiksy's letter to the editor

The frequency and influence of dementia risk factors in prodromal Alzheimer's disease

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort

[Administration of symptom-relieving drugs in Alzheimer disease is beneficial]